Kawasaki et al. reported that FAM111B promotes the proliferation of KRAS-driven lung adenocarcinoma by degrading p16, suggesting a clinicopathological marker for predicting LUAD prognosis 33. Here, KRAS is linked to lung adenocarcinoma.